Strategic partnerships CellCarta’s growing ecosystem of alliances with Tempus, Sonic Healthcare, Pillar Biosciences, Leinco Technologies and Lunit signals a strong opportunity to position cross-network CDx and companion diagnostics services to biopharma sponsors through co-developed solutions and expanded lab network reach.

Global reach With facilities across North America, Europe, Australia and Asia, CellCarta offers geographically distributed testing capabilities that can support multinational clinical trials, enabling you to pitch scalable testing programs and localized regulatory-compliant workflows.

Digital pathology leadership The launch of the Global Digital Pathology and AI Consortium highlights a commitment to AI-driven biomarker discovery and patient stratification, presenting a sales angle for integrated digital pathology, AI-enabled analytics, and standardized translational workflows.

Regulatory readiness Professsional accreditations such as CAP, CLIA, ISO15189, ISO27001 and ISO13485 indicate a robust quality framework, allowing you to target sponsors prioritizing compliance-heavy, regulatory-grade testing and seamless entry into regulated trials.

Diversified tech stack CellCarta’s suite spanning immunology, histopathology, proteomics, genomics, digital pathology/AI and sample management suggests cross-sell opportunities across multiple biomarkers and assay platforms, as well as collaborations around AI-driven analytics and integrated data solutions.